New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
08:11 EDTCCRN, HITK, AEZS, AMED, IMGN, HTWR, CRVL, SQNM, MDAS, DSCIOppenheimer to host a conference
23rd Annual Healthcare Conference is being held in New York on December 12-13 with webcasted presentations to begin on December 13 at 7:45 am; not all presentations may be webcasted. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
06:35 EDTIMGNImmunoGen lowers FY15 revenue view to $85M-$95M from $100M-$105M
Consensus for FY15 revenue is $101.12M. Backs FY15 net loss view of $60M-$65M. Raises FY15 cash and cash equivalents at June 30 to $265M-$275M from $75M-$85M.
06:32 EDTIMGNImmunoGen reports Q3 EPS (25c), consensus (24c)
Reports Q3 revenue $11.4M, consensus $20.95M.
April 23, 2015
08:44 EDTMDASMedAssets expands relationship with Vanderbilt University Medical Center
MedAssets announced Vanderbilt University Medical Center, or VUMC, has selected the company to provide Lean Healthcare Transformation & Integration Consulting services for operational process and performance improvement across its care continuum. The new 18-month engagement largely focused on VUMC's clinical departments will use innovative education, advanced problem-solving techniques and rapid improvement initiatives to guide VUMC staff in affecting and sustaining change. The agreement builds upon momentum created from Lean project engagements completed in 2014 as part of MedAssets longstanding relationship with VUMC.
April 20, 2015
07:29 EDTHTWRCanaccord would be buyers of Thoratec following favorable ISHLT
Subscribe for More Information
07:26 EDTHTWRHeartWare weakness a buying opportunity, says Canaccord
Subscribe for More Information
07:20 EDTIMGNAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 16, 2015
15:50 EDTDSCIJames Flynn reports 5.32% passive stake in Derma Sciences
Subscribe for More Information
09:52 EDTHTWRThoratec comments on HeartMate II data in ENDURANCE therapy trial
Subscribe for More Information
08:53 EDTHTWRBofA/Merrill medical technology analysts hold analyst/industry conference call
Subscribe for More Information
07:37 EDTAEZSAeterna Zentaris files additional patent application for zoptarelin doxorubicin
Subscribe for More Information
05:32 EDTHTWRHeartWare achieves primary endpoint in ENDURANCE clinical trial
Subscribe for More Information
April 15, 2015
07:41 EDTAEZSEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
10:01 EDTAEZSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:08 EDTAEZSAeterna Zentaris upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Aeterna Zentaris to Buy with a $1.25 price target following the successful meeting with the FDA for a new Phase 3 trial of Macrilen and a separate, thorough QT study to address issues raised by the Complete Response Letter in November 2014.
April 13, 2015
10:15 EDTSQNMHigh option volume stocks
Subscribe for More Information
07:34 EDTAEZSAeterna Zentaris plans to conduct new Phase 3 clinical study of Macrilen
Aeterna Zentaris announced plans to conduct a new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen, or macimorelin, a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency, as well as a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarization. This decision follows a positive and helpful meeting with the FDA regarding its New Drug Application for Macrilen. The Company's goal is to conduct a Phase 3 study that will satisfy the registration requirements of the European Medicines Agency as well as the FDA. The Company expects to receive comments from the EMA regarding the study design during a Scientific Advice Meeting in early May.
April 11, 2015
14:10 EDTHTWRLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use